Guardant Health
banner
guardanthealth.bsky.social
Guardant Health
@guardanthealth.bsky.social
110 followers 53 following 74 posts
Conquering Cancer With Data🩸
Posts Media Videos Starter Packs
We have reported our third quarter 2025 financial results, highlighted by 39% year-over-year revenue growth.

Our continued momentum has led us to raise our full-year 2025 revenue guidance to $965–$970 million, representing 31% year-over-year growth.

Details: bit.ly/4nBoZaJ
We're sharing data at #ACG2025, highlighting the critical role of blood-based testing in improving #CancerScreening adherence.

Data presentation details: bit.ly/4odIp6K
We’re excited to be at #JADPROLive in National Harbor, Maryland!

Stop by Booth #510 to meet our medical affairs team and explore the vital role oncology advanced practitioners play in advancing precision cancer care through molecular testing.
We’re excited to share our latest data this week at #ESMO25!

📍Visit us at Booth 3021 to learn more.

Additional details: bit.ly/4nVIQCu
We’re proud to share that the FDA has approved our Guardant360® CDx test as a companion diagnostic for
@elilillyandcompany.bsky.social's Inluriyo™ (imlunestrant)
for ESR1-mutated advanced #BreastCancer.

More details: investors.guardanthealth.com/press-releas...
We’re proud to be a partner of the World Clinical Biomarkers & Companion Diagnostics Summit next week.

Join our plenary session with Jean-Francois Martini to learn how our flexible solutions combined with multimodal real-world data and can streamline your #ClinicalDevelopment program for success.
We are proud to welcome Alex M. Azar II to our board of directors. Secretary Azar brings a unique perspective on the intersection of policy, innovation, and patient access that will help us advance our mission to conquer cancer with data.

Details: bit.ly/4gmjZom
Today we’re excited to announce a new partnership with
PathGroup to expand access to our Shield™ #BloodTest for early cancer detection.

Through PathGroup’s extensive network, Shield will soon be available in more than 250 hospitals and 15,000 physicians across 25 states.

Details: bit.ly/4peK392
On Tuesday, our Co-CEO Helmy Eltoukhy will join
@wired.com at #WIREDHealth for a featured conversation: “Winning the War on Cancer."

Helmy will explore how liquid biopsies are driving earlier detection, faster treatment decisions, & a more personalized patient experience.

Info: lnkd.in/e3KvKNsa
This past weekend, we teamed up with the Dolphins Cancer Challenge before the Dolphins took on the Jaguars to connect with fans and share more about Shield™, the blood test that screens for #ColonCancer the more pleasant way.

A big #ThankYou to all the fans who joined the conversation with us!
Today we announced that the 1st patient has been enrolled in the the National Cancer Institute's Vanguard Study, evaluating our Shield™ MCD test.

The 4-year study will assess the feasibility of using blood-based tests to detect multiple cancers in individuals w/o symptoms.

Details: bit.ly/40jXcms
Join us for a live #Webinar on the power of epigenomic biomarkers to improve patient selection and better predict treatment response in oncology clinical trials.

Register today: bit.ly/44kpIa3
📅 Date: July 24
🕘 Time: 9:00am PT
Last week, our co-CEO AmirAli Talasaz took the stage at #AspenIdeasHealth on the New Frontiers in Cancer panel, a timely discussion on how breakthroughs in blood-based screening, precision medicine, & AI are reshaping the future of care.

Watch the session: bit.ly/4kt5yQ0

Photo credit: Leigh Vogel
At #AspenIdeasHealth, our co-CEO AmirAli Talasaz sat down with @drjohntorres.bsky.social to discuss a critical gap in cancer care: screening technologies are advancing, but access isn’t keeping pace.
Exciting news! Our Shield™ blood test has been recognized on @fastcompany.com's 2025 World Changing Ideas list! We're thrilled to be part of this amazing collection of ideas driving meaningful change in the world.

Check out the full list here: fastcompany.com/world-changi...

#FCWorldChangingIdeas
Today, we’re proud to share that ESMO Open has published results from the LIBERATE study, highlighting Guardant Reveal’s performance in detecting minimal residual disease in early-stage #BreastCancer.

Details: bit.ly/43yOanC
We're honored to announce that our Shield multi-cancer detection (MCD) test has been granted Breakthrough Device designation from the @fda.gov.

More details: investors.guardanthealth.com/press-releas...
Featured in @nytimes.com: Our Guardant360® CDx test is helping revolutionize #BreastCancer treatment by detecting drug resistance before it shows up on scans—enabling timely treatment changes and improving patient outcomes.
Drug-Defying Breast Cancers Spotted Early in Blood Test Study
www.nytimes.com
We’re proud to share that the National Comprehensive Cancer Network has included our Shield™ blood test in its updated #ColorectalCancer screening guidelines. Marking a pivotal step forward in expanding #PatientAccess to an innovative, blood-based screening option.

Details: bit.ly/3SxrayX
Today we announced results from the Phase III SERENA-6 trial, demonstrating the clinical value of our Guardant360® CDx test in detecting & treating emerging resistance in advanced #BreastCancer ahead of radiological progression.

Details: bit.ly/4mJ3kxU
The future of precision oncology is here.

Join us at #ASCO25, booth #25077, to discover the pivotal role of liquid biopsy in transforming cancer care and improving patient outcomes.
At #ASCO25 yesterday, we shared results from the largest study to date evaluating ctDNA in #ColonCancer, highlighting the power of our Guardant Reveal™ test to inform critical treatment decisions.

More details: bit.ly/4mFFHq1
Join us at #ASCO25 for an exclusive event showcasing how our Guardant Infinity™ platform is propelling patient-centered care into the future. Discover how redefining precision oncology through innovation & advocacy.

📅 Monday, June 2
🕗 8 AM–5 PM
📍 Marriott Marquis Chicago | Astronomy Room